NCT03394391

Brief Summary

The non-maintenance of ART adherence is a major barrier to the achievement of optimal treatment outcomes among adolescents living with HIV. ART adherence is a challenge among adolescents living with HIV because of lack of appropriate information, their unique emotional state and lifestyles but the most commonly quoted challenge to adherence is forgetting to take antiretroviral drugs. There is evidence to suggest that short message service (SMS) reminder- interventions may enhance drug compliance among adolescents living with other chronic diseases such as asthma and diabetes. Available literature underscores the need for randomized controlled trials (RCTs) of effective interventions to promote ART adherence among adolescents with HIV. The aim of this study is to evaluate the feasibility, acceptability, and efficacy of interactive and tailored SMS reminders on ART adherence among adolescents (15-19 years) living with HIV in Ogun State, Nigeria. The study hypothesizes that the use of personal mobile phones and SMS reminders for the improvement of ART adherence among adolescents living with HIV are feasible, acceptable, and effective. A single-blind, parallel-design (ratio 1:1), and multi-center RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria. All the participants will receive routine adherence counseling during clinic visits and one SMS reminder each for follow-up appointments 48 hours and 24 hours before the follow-up visit date. The intervention group will also receive daily ART adherence reminder SMS. Participants will be assessed at baseline and during follow-up visits at 4, 8, 12, 16 and 20 weeks after the baseline. Baseline assessment of participants will include socio-demographic characteristics; HIV/AIDS risk behaviour assessment, Alcohol and Drug abuse assessment, Client Satisfaction Survey, ART adherence assessment, CD4count and viral load assessments. ART adherence and client satisfaction will be assessed at each follow-up visit while CD4count and viral load assessments will be done at baseline and at 20th week. It is possible that tailored SMS reminders will mitigate the barrier of forgetfulness in ART-adherence and lead to improved drug compliance, viral suppression, and quality of life among adolescents living with HIV.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
212

participants targeted

Target at P50-P75 for not_applicable hiv-infections

Timeline
Completed

Started Jul 2018

Shorter than P25 for not_applicable hiv-infections

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 28, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 9, 2018

Completed
6 months until next milestone

Study Start

First participant enrolled

July 5, 2018

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 3, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2019

Completed
5 months until next milestone

Results Posted

Study results publicly available

November 15, 2019

Completed
Last Updated

November 15, 2019

Status Verified

November 1, 2019

Enrollment Period

10 months

First QC Date

December 28, 2017

Results QC Date

September 14, 2019

Last Update Submit

November 13, 2019

Conditions

Keywords

AdherenceAdolescentsAntiretroviral therapyHIVNigeriaRandomized controlled trialShort message services

Outcome Measures

Primary Outcomes (4)

  • ART Adherence at 20 Weeks as Determined by VAS, Viral Load

    ART adherence is assessed by different well-validated methods. In this study, ART adherence will be measured, primarily, using the self-report visual analog scale. The scale is well-validated, self-report of the level of ART adherence with a range from 0 to 100%. While higher values indicate better levels of adherence, patients with adherence levels of 95% and above are regarded as ART-adherent while those with values less than 95% are not adherent to ART medications. Viral load is the number of copies of viral RNA detected in participants' blood. Participants with viral load \</=20 copies per ml are regarded to have optimal viral suppression indicative of optimal adherence to medications.

    20week [End of study]

  • ART Adherence at 20 Weeks as Determined by Pill Counts, ACTG Adherence Questionnaire, and VAS Scores

    AIDS Clinical Trials Group Scale scores range from 0 to 1. The higher scores reflect better ART adherence Pill count scores also range from 0 to 1 and the higher scores also reflect better adherence. Visual analog scale \[VAS\] adherence ranges between 0 and 100%. Higher scores reflect better ART adherence

    20week [End of study]

  • ART Adherence at 20 Weeks as Determined by Viral Load Count

    Viral load count is measured in copies per ml. The minimum value is 0. There is no maximum value. The higher values reflect poor adherence

    20 week [End of study]

  • ART Adherence at 20 Weeks as Determined by Log of Viral Load Count

    log of viral load count is log 10 transformation of the viral load values

    20week [End of study]

Secondary Outcomes (2)

  • Patient Satisfaction Score at 20 Weeks

    End of Study (20weeks)

  • Number of Participants With Mental Distress Determined by General Health Questionnaire 12 at 20 Weeks

    End of study (20weeks)

Study Arms (2)

Intervention group

EXPERIMENTAL

Daily ART-adherence SMS reminder

Behavioral: Daily ART-adherence SMS reminderBehavioral: Standard Adherence Counselling/Patient experience group chat

Control group

ACTIVE COMPARATOR

Standard adherence counselling/Patient experience group chat

Behavioral: Standard Adherence Counselling/Patient experience group chat

Interventions

Interactive and tailored SMS reminders that are acceptable to the participants to remind them to take their medications and to make clinic attendance.

Intervention group

All the participants will receive the standard adherence counselling by trained counsellors at each visit. All participants will also be enlisted in a group chat on social media where they will discuss their experiences with the quality of HIV services rendered at their respective clinics. A specialist who will have very minimal involvement will give weekly feedback and counsel on how best to resolve prominent challenges.

Control groupIntervention group

Eligibility Criteria

Age15 Years - 19 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • HIV seropositivity
  • Being on ART for at least three month
  • Age 15 to 19 years as at last birthday
  • Use of personal mobile phone
  • Poor adherence to ART

You may not qualify if:

  • Adolescents who are too ill to require hospital admission will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Lagos State University Teaching Hospital

Ikeja, Lagos, Nigeria

Location

The Nigerian Institute of Medical Research

Yaba, Lagos, Nigeria

Location

Federal Medical Center

Abeokuta, Ogun State, Nigeria

Location

State Hospital

Ijebu Ode, Ogun State, Nigeria

Location

State Hospital

Ota, Ogun State, Nigeria

Location

Related Publications (28)

  • Dowshen N, Kuhns LM, Johnson A, Holoyda BJ, Garofalo R. Improving adherence to antiretroviral therapy for youth living with HIV/AIDS: a pilot study using personalized, interactive, daily text message reminders. J Med Internet Res. 2012 Apr 5;14(2):e51. doi: 10.2196/jmir.2015.

    PMID: 22481246BACKGROUND
  • Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18.

    PMID: 21767103BACKGROUND
  • McMahon JH, Elliott JH, Bertagnolio S, Kubiak R, Jordan MR. Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ. 2013 May 1;91(5):377-385E. doi: 10.2471/BLT.12.112946. Epub 2013 Feb 21.

    PMID: 23678201BACKGROUND
  • Naar-King S, Templin T, Wright K, Frey M, Parsons JT, Lam P. Psychosocial factors and medication adherence in HIV-positive youth. AIDS Patient Care STDS. 2006 Jan;20(1):44-7. doi: 10.1089/apc.2006.20.44.

    PMID: 16426155BACKGROUND
  • Rao D, Kekwaletswe TC, Hosek S, Martinez J, Rodriguez F. Stigma and social barriers to medication adherence with urban youth living with HIV. AIDS Care. 2007 Jan;19(1):28-33. doi: 10.1080/09540120600652303.

    PMID: 17129855BACKGROUND
  • Glikman D, Walsh L, Valkenburg J, Mangat PD, Marcinak JF. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications. Pediatrics. 2007 May;119(5):e1142-8. doi: 10.1542/peds.2006-2614. Epub 2007 Apr 23.

    PMID: 17452493BACKGROUND
  • Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med. 2009 Feb;36(2):165-73. doi: 10.1016/j.amepre.2008.09.040.

    PMID: 19135907BACKGROUND
  • Wei J, Hollin I, Kachnowski S. A review of the use of mobile phone text messaging in clinical and healthy behaviour interventions. J Telemed Telecare. 2011;17(1):41-8. doi: 10.1258/jtt.2010.100322. Epub 2010 Nov 19.

    PMID: 21097565BACKGROUND
  • Hung SH, Tseng HC, Tsai WH, Lin HH, Cheng JH, Chang YM. Care for Asthma via Mobile Phone (CAMP). Stud Health Technol Inform. 2007;126:137-43.

    PMID: 17476056BACKGROUND
  • Franklin VL, Waller A, Pagliari C, Greene SA. A randomized controlled trial of Sweet Talk, a text-messaging system to support young people with diabetes. Diabet Med. 2006 Dec;23(12):1332-8. doi: 10.1111/j.1464-5491.2006.01989.x.

    PMID: 17116184BACKGROUND
  • Miloh T, Annunziato R, Arnon R, Warshaw J, Parkar S, Suchy FJ, Iyer K, Kerkar N. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. Pediatrics. 2009 Nov;124(5):e844-50. doi: 10.1542/peds.2009-0415. Epub 2009 Oct 12.

    PMID: 19822583BACKGROUND
  • Lester RT, Mills EJ, Kariri A, Ritvo P, Chung M, Jack W, Habyarimana J, Karanja S, Barasa S, Nguti R, Estambale B, Ngugi E, Ball TB, Thabane L, Kimani J, Gelmon L, Ackers M, Plummer FA. The HAART cell phone adherence trial (WelTel Kenya1): a randomized controlled trial protocol. Trials. 2009 Sep 22;10:87. doi: 10.1186/1745-6215-10-87.

    PMID: 19772596BACKGROUND
  • Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD009756. doi: 10.1002/14651858.CD009756.

    PMID: 22419345BACKGROUND
  • Heron KE, Smyth JM. Ecological momentary interventions: incorporating mobile technology into psychosocial and health behaviour treatments. Br J Health Psychol. 2010 Feb;15(Pt 1):1-39. doi: 10.1348/135910709X466063. Epub 2009 Jul 28.

    PMID: 19646331BACKGROUND
  • Cole-Lewis H, Kershaw T. Text messaging as a tool for behavior change in disease prevention and management. Epidemiol Rev. 2010;32(1):56-69. doi: 10.1093/epirev/mxq004. Epub 2010 Mar 30.

    PMID: 20354039BACKGROUND
  • Kalichman SC, Amaral CM, Swetzes C, Jones M, Macy R, Kalichman MO, Cherry C. A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care (Chic). 2009 Nov-Dec;8(6):367-74. doi: 10.1177/1545109709352884.

    PMID: 19952289BACKGROUND
  • Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004 Mar-Apr;5(2):74-9. doi: 10.1310/JFXH-G3X2-EYM6-D6UG.

    PMID: 15116282BACKGROUND
  • Kalichman SC, Kalichman MO, Cherry C, Swetzes C, Amaral CM, White D, Jones M, Grebler T, Eaton L. Brief behavioral self-regulation counseling for HIV treatment adherence delivered by cell phone: an initial test of concept trial. AIDS Patient Care STDS. 2011 May;25(5):303-10. doi: 10.1089/apc.2010.0367. Epub 2011 Apr 2.

    PMID: 21457056BACKGROUND
  • Bam K, Rajbhandari RM, Karmacharya DB, Dixit SM. Strengthening adherence to Anti Retroviral Therapy (ART) monitoring and support: operation research to identify barriers and facilitators in Nepal. BMC Health Serv Res. 2015 May 5;15:188. doi: 10.1186/s12913-015-0846-8.

    PMID: 25939593BACKGROUND
  • Watt MH, Maman S, Golin CE, Earp JA, Eng E, Bangdiwala SI, Jacobson M. Factors associated with self-reported adherence to antiretroviral therapy in a Tanzanian setting. AIDS Care. 2010 Mar;22(3):381-9. doi: 10.1080/09540120903193708.

    PMID: 20390519BACKGROUND
  • Montazeri A, Harirchi AM, Shariati M, Garmaroudi G, Ebadi M, Fateh A. The 12-item General Health Questionnaire (GHQ-12): translation and validation study of the Iranian version. Health Qual Life Outcomes. 2003 Nov 13;1:66. doi: 10.1186/1477-7525-1-66.

    PMID: 14614778BACKGROUND
  • Purdy JB, Freeman AF, Martin SC, Ryder C, Elliott-DeSorbo DK, Zeichner S, Hazra R. Virologic response using directly observed therapy in adolescents with HIV: an adherence tool. J Assoc Nurses AIDS Care. 2008 Mar-Apr;19(2):158-65. doi: 10.1016/j.jana.2007.08.003.

    PMID: 18328966BACKGROUND
  • Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, de Walque D, MacKeen L, Haberer J, Kimaiyo S, Sidle J, Ngare D, Bangsberg DR. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS. 2011 Mar 27;25(6):825-34. doi: 10.1097/QAD.0b013e32834380c1.

    PMID: 21252632BACKGROUND
  • Donenberg GR, Schwartz RM, Emerson E, Wilson HW, Bryant FB, Coleman G. Applying a cognitive-behavioral model of HIV risk to youths in psychiatric care. AIDS Educ Prev. 2005 Jun;17(3):200-16. doi: 10.1521/aeap.17.4.200.66532.

    PMID: 16006207BACKGROUND
  • Nugent NR, Brown LK, Belzer M, Harper GW, Nachman S, Naar-King S; Adolescent Trials Network for HIV/AIDS Interventions. Youth living with HIV and problem substance use: elevated distress is associated with nonadherence and sexual risk. J Int Assoc Physicians AIDS Care (Chic). 2010 Mar-Apr;9(2):113-5. doi: 10.1177/1545109709357472. Epub 2010 Feb 4.

    PMID: 20133498BACKGROUND
  • Shacham E, Estlund A, Presti R. Viral suppression among young adults in a US outpatient clinic. BMC Infectious Diseases 14(Suppl 2): P76, 2014. https://doi.org/10.1186/1471-2334-14-S2-P76

    BACKGROUND
  • Abiodun O, Jagun O, Sodeinde K, Bamidele F, Adekunle M, David A. Socioeconomic, clinical, and behavioral characteristics of adolescents living with HIV in Southwest Nigeria: implication for preparedness for transition to adult care. AIDS Care. 2022 Mar;34(3):315-323. doi: 10.1080/09540121.2021.1906402. Epub 2021 Mar 25.

  • Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.

Related Links

MeSH Terms

Conditions

HIV Infections

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Results Point of Contact

Title
Dr. Olumide ABIODUN
Organization
Babcock University

Study Officials

  • Olumide ABIODUN, FWACP

    Babcock University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The investigators, data manager, research assistants, counselors and other project staff will be blinded throughout the study. An independent medical internet technology firm will be contracted to randomize participants and to send the required SMS to the participants. After scientific review has been completed and data collection has been completed, at the point of analysis, a list of participants' unique identifiers in two groups will be sent to the data analysts without specifying which the investigation or control group is. The blinding of the clinical database will finally be removed after final data analysis has been completed.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: A single-blind, parallel-design (ratio 1:1), and multi-centre RCT of 230 adolescent living with HIV who are non-adherent to medications will be conducted over a one-year period in Southwest Nigeria.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Senior Lecturer and Honorary Consultant

Study Record Dates

First Submitted

December 28, 2017

First Posted

January 9, 2018

Study Start

July 5, 2018

Primary Completion

May 3, 2019

Study Completion

June 30, 2019

Last Updated

November 15, 2019

Results First Posted

November 15, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will share

(De-identified) IPD may be shared with other researchers upon reasonable request

Shared Documents
STUDY PROTOCOL
Time Frame
June 30th, 2019 to June 29th, 2020
Access Criteria
Open access Other information will be available upon reasonable request

Locations